In the currently ongoing 2024 dengue outbreak in Latin America and the Caribbean, the number of reported infections surpassed historical records in several nations with a combined total of over 13 million suspected cases on 9 January 2024 and 8,186+ deaths.

[3] A comprehensive multinational study published in Nature Communications found that climate change and increased human mobility were significant factors contributing to the rapid acceleration in the spread of dengue.

[4] Other studies indicate that the increased temperatures related to the El Niño weather pattern also contributed to the exceptionally high number of dengue fever cases and area covered.

[5] Four dengue virus serotypes: DENV1, DENV2, DENV3 and DENV4, were found to be simultaneously circulating in all of the impacted countries in Central America aside from El Salvador, which currently only had DENV1, DENV2, and DENV3 confirmed.

The greatest concentration of cases are currently ongoing in the departments of Tegucigalpa, Cortés, San Pedro Sula, Bay Islands, Atlántida, and La Paz.

Another possible factor regards economic disparities in marginalized urban areas leading to delays in treatment allowing for the infection to spread in the densely populated environment.

Poor waste management, water collection practices, and sanitation in part due to shortages of cleaning supplies prevented the disease from being contained.

[8] In order to slow the spread of the disease and work to achieve herd immunity, Brazil preemptively purchased the entire global stock of Qdenga dengue two-dose vaccine made by the Japanese pharmaceutical company Takeda in January 2024.